Asthma control during and after cessation of regular beta 2-agonist treatment.
Asthma control during and after cessation of regular beta 2-agonist treatment.
复制标题
常规 β2 激动剂治疗期间和停止后的哮喘控制。
DOI：
10.1164/ajrccm/148.3.707
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
A. Tattersfield
中科院分区：
文献类型：
--
作者：
I. Wahedna;C S Wong;A. Wisniewski;I. Pavord;A. Tattersfield
有人建议，定期使用高剂量的 β2 激动剂治疗可能会导致哮喘控制较差并增加支气管反应性。我们检查了使用相对较低剂量的沙丁胺醇和布沙特罗（一种新型 β2 激动剂）常规治疗期间和之后 3 周的 FEV1 (delta FEV1)、支气管反应性、呼气峰流量 (PEF) 以及症状的变化。 11 名 18 至 50 岁患有轻度哮喘的受试者每天吸入沙丁胺醇（200 微克）、布沙特罗（400 微克）或安慰剂，持续 3 周，治疗之间有 2 至 4 周的磨合/洗脱期。允许使用异丙托溴铵来缓解症状。在停止治疗前和停止治疗后 11、35 和 59 小时测量 PD20（导致 FEV1 下降 20% 的组胺剂量），并在停止治疗前和停止治疗后 83 小时进行支气管扩张剂剂量反应研究。将沙丁胺醇和布沙特罗后相对于基线的变化与安慰剂后的变化进行比较。沙丁胺醇治疗期间 PEF 的日变化（平均幅度％）增加了 6.5%（95% CI，1.7-12.3；p < 0.02），主要是因为早晨 PEF 下降。与安慰剂相比，停止使用两种 β2 激动剂治疗与 FEV1 和 PD20 下降相关。（摘要截断为 250 字）
It has been suggested that regular treatment with high doses of beta 2-agonists might result in poorer control of asthma and increased bronchial responsiveness. We have examined change in FEV1 (delta FEV1), bronchial reactivity, peak expiratory flow (PEF), and symptoms during and after 3 wk of regular treatment with a relatively low dose of albuterol and broxaterol, a new beta 2-agonist. Eleven subjects 18 to 50 yr of age with mild asthma inhaled albuterol (200 micrograms), broxaterol (400 micrograms), or placebo three times a day for 3 wk with a 2- to 4-wk run-in/washout period between treatments. Ipratropium bromide was allowed for symptomatic relief. The PD20 (dose of histamine causing a 20% fall in FEV1) was measured before and 11, 35, and 59 h after cessation of treatment and a bronchodilator dose-response study before and 83 h after cessation of treatment. Change from baseline after albuterol and broxaterol are compared with change after placebo. Diurnal change in PEF (amplitude % mean) increased during treatment with albuterol by 6.5% (95% CI, 1.7-12.3; p < 0.02) mainly because of a fall in morning PEF. Cessation of treatment with both beta 2-agonists was associated with a fall in FEV1 and PD20 compared with placebo.(ABSTRACT TRUNCATED AT 250 WORDS)